Dosimetric analyses of intra-arterial versus standard intravenous administration of 177Lu-DOTATATE in patients of well differentiated neuroendocrine tumor with liver-dominant metastatic disease

Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study

(2020) Jonathan Strosberg et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial)

(2020) Sander C. Ebbers et al.   Trials

Dosimetric analysis of patients with gastro-entero-pancreatic neuro endocrine tumors (NETs) treated with PRCRT (Peptide Receptor Chemo Radionuclide Therapy) using Lu-177 DOTATATE and Capecitabine/Temozolamide (CAP/TEM)

(2018) Parul Thakral et al.   BRITISH JOURNAL OF RADIOLOGY

Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry

(2017) Anna Sundlöv et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study

(2017) Michela Del Prete et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Dose Response of Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE

(2015) E. Ilan et al.   JOURNAL OF NUCLEAR MEDICINE

[111In-DTPA]octreotide Tumor Uptake in GEPNET Liver Metastases After Intra-Arterial Administration: An Overview of Preclinical and Clinical Observations and Implications for Tumor Radiation Dose After Peptide Radionuclide Therapy

(2014) Stefan E. Pool et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Individualized Dosimetry of Kidney and Bone Marrow in Patients Undergoing 177Lu-DOTA-Octreotate Treatment

(2012) M. Sandstrom et al.   JOURNAL OF NUCLEAR MEDICINE

Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases

(2011) Clemens Kratochwil et al.   ENDOCRINE-RELATED CANCER

Intraindividual Comparison of Selective Arterial versus Venous 68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors

(2010) C. Kratochwil et al.   CLINICAL CANCER RESEARCH

Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival

(2008) Dik J. Kwekkeboom et al.   JOURNAL OF CLINICAL ONCOLOGY